Latest stories on SYRE
Spyre Therapeutics Non-GAAP EPS of -$0.36 beats by $0.39
Seeking Alpha68 · bullishearnings
Spyre Therapeutics, Inc. (SYRE) files 8-K
SEC 8-K50 · neutralgeneral
Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
StockTitan59 · neutralearnings
Spyre Therapeutics Announces Grants of Inducement Awards | SYRE Stock News
StockTitan50 · neutralgeneral
Spyre Therapeutics: Deep And Diverse Immunology Pipeline Awaiting Data
Seeking Alpha56 · neutralanalyst
Spyre Therapeutics: A Platform Where The Combination Strategy Is The Real Asset
Seeking Alpha63 · neutralproduct/pr
Spyre Therapeutics Shares Slide Following Large Insider Stock Sales (SYRE)
Yahoo Top34 · bearishgeneral
Spyre Therapeutics Extends Long-Acting Antibody Program in IBD With New Long-Term Study
TipRanks63 · neutralproduct/pr
Spyre Therapeutics Reports Strong Phase 2 SKYLINE Results
TipRanks73 · bullishproduct/pr
Spyre Therapeutics, Inc. (SYRE) files 8-K
SEC 8-K50 · neutralgeneral
Spyre Therapeutics, Inc. (SYRE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha56 · neutralgeneral
Spyre Therapeutics Announces Grants of Inducement Awards | SYRE Stock News
StockTitan50 · neutralgeneral
Spyre Therapeutics (SYRE): 12 Best High Short Interest Stocks With Highest Upside Potential
Yahoo Top58 · neutralgeneral
Spyre Expands SPY003 Rights Beyond Inflammatory Bowel Disease
TipRanks63 · neutralproduct/pr
Spyre Therapeutics to Participate in Upcoming June Investor Conferences | SYRE Stock News
StockTitan56 · neutralgeneral